Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
- PMID:11181778
- DOI: 10.1093/jnci/93.4.309
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
Abstract
Background: Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that regulates gene expression in critical pathways involved in tumor growth and metastases. In this report, we investigated whether the level of HIF-1 alpha is increased during carcinogenesis in breast tissue and is associated with other tumor biomarkers.
Methods: Paraffin-embedded clinical specimens from five pathologic stages of breast tumorigenesis and from normal breast tissue were used. HIF-1 alpha protein and the biomarkers vascular endothelial growth factor (VEGF), HER-2/neu, p53, Ki-67, and estrogen receptor (ER) were identified immunohistochemically, and microvessel density (a measure of angiogenesis) was determined. Associations among levels of HIF-1 alpha and these biomarkers were tested statistically. All statistical tests are two-sided.
Results: The frequency of HIF-1 alpha-positive cells in a specimen increased with the specimen's pathologic stage (P<.001, chi(2) test for trend) as follows: normal breast tissue (0 specimens with > or = 1% HIF-1 alpha-positive cells in 10 specimens tested), ductal hyperplastic lesions (0 in 10), well-differentiated ductal carcinomas in situ (DCIS) (11 in 20), well-differentiated invasive breast cancers (12 in 20), poorly differentiated DCIS (17 in 20), and poorly differentiated invasive carcinomas (20 in 20). Increased levels of HIF-1 alpha were statistically significantly associated with high proliferation and increased expression of VEGF and ER proteins. In DCIS lesions, increased levels of HIF-1 alpha were statistically significantly associated with increased microvessel density. HIF-1alpha showed a borderline association with HER-2/neu but no association with p53.
Conclusions: The level of HIF-1 alpha increases as the pathologic stage increases and is higher in poorly differentiated lesions than in the corresponding type of well-differentiated lesions. Increased levels of HIF-1 alpha are associated with increased proliferation and increased expression of ER and VEGF. Thus, increased levels of HIF-1 alpha are potentially associated with more aggressive tumors.
Comment in
- Re: Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis.Costa A, Coradini D, Carrassi A, Erdas R, Sardella A, Daidone MG.Costa A, et al.J Natl Cancer Inst. 2001 Aug 1;93(15):1175-7. doi: 10.1093/jnci/93.15.1175-a.J Natl Cancer Inst. 2001.PMID:11481392No abstract available.
Similar articles
- Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.Lee JS, Kim HS, Jung JJ, Kim YB, Lee MC, Park CS.Lee JS, et al.Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):289-95. doi: 10.1097/00129039-200212000-00001.Appl Immunohistochem Mol Morphol. 2002.PMID:12607595
- A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts.Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo H.Kurebayashi J, et al.Jpn J Cancer Res. 2001 Dec;92(12):1342-51. doi: 10.1111/j.1349-7006.2001.tb02159.x.Jpn J Cancer Res. 2001.PMID:11749701Free PMC article.
- Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI; Tumor and Angiogenesis Research Group.Sivridis E, et al.Cancer. 2002 Sep 1;95(5):1055-63. doi: 10.1002/cncr.10774.Cancer. 2002.PMID:12209691
- Hypoxia-induced angiogenesis during carcinogenesis.Choi KS, Bae MK, Jeong JW, Moon HE, Kim KW.Choi KS, et al.J Biochem Mol Biol. 2003 Jan 31;36(1):120-7. doi: 10.5483/bmbrep.2003.36.1.120.J Biochem Mol Biol. 2003.PMID:12542982Review.
- HIF-1: using two hands to flip the angiogenic switch.Semenza GL.Semenza GL.Cancer Metastasis Rev. 2000;19(1-2):59-65. doi: 10.1023/a:1026544214667.Cancer Metastasis Rev. 2000.PMID:11191064Review.
Cited by
- Hypoxia in Breast Cancer-Scientific Translation to Therapeutic and Diagnostic Clinical Applications.Zhang Y, Zhang H, Wang M, Schmid T, Xin Z, Kozhuharova L, Yu WK, Huang Y, Cai F, Biskup E.Zhang Y, et al.Front Oncol. 2021 Mar 11;11:652266. doi: 10.3389/fonc.2021.652266. eCollection 2021.Front Oncol. 2021.PMID:33777815Free PMC article.Review.
- VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis.Seagroves TN, Peacock DL, Liao D, Schwab LP, Krueger R, Handorf CR, Haase VH, Johnson RS.Seagroves TN, et al.Am J Pathol. 2010 May;176(5):2269-82. doi: 10.2353/ajpath.2010.090310. Epub 2010 Apr 9.Am J Pathol. 2010.PMID:20382704Free PMC article.
- Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast.Kuijper A, van der Groep P, van der Wall E, van Diest PJ.Kuijper A, et al.Breast Cancer Res. 2005;7(5):R808-18. doi: 10.1186/bcr1296. Epub 2005 Aug 5.Breast Cancer Res. 2005.PMID:16168127Free PMC article.
- Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.Rice A, Quinn CM.Rice A, et al.J Clin Pathol. 2002 Aug;55(8):569-74. doi: 10.1136/jcp.55.8.569.J Clin Pathol. 2002.PMID:12147647Free PMC article.Review.
- Employing tumor hypoxia for oncolytic therapy in breast cancer.Chun YS, Adusumilli PS, Fong Y.Chun YS, et al.J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):311-8. doi: 10.1007/s10911-006-9004-6.J Mammary Gland Biol Neoplasia. 2005.PMID:16826462Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous